Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA
Executive Summary
Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)